Vebicorvir

SKU: orb1298264

Description

Vebicorvir (ABI-H0731) is a first-generation HBV core protein allosteric modulator that potently inhibits viral replication. It has demonstrated significant antiviral activity in both in vitro assays and in vivo preclinical studies, supporting its investigation as a potential therapeutic agent for chronic hepatitis B.

Research Area

Infectious Disease & Virology

Key Properties

• CAS Number: 2090064-66-5
• MW: 467.44
• Purity: 99.51% (May vary between batches)
• Formula: C₁₉H₁₂F₃N₃O₄S₂
• SMILES: FC(F)(F)c1ncc(CNC(=O)c2ccc3c(NC(=O)c4ccccc4S3(=O)=O)c2)s1
• Target: HBV
• Solubility: 10% DMSO+90% Corn Oil:2.5 mg/mL (5.35 mM);DMSO:60 mg/mL (128.36 mM)

Bioactivity

• In Vitro:
  Vebicorvir exhibited selective inhibition of HBV DNA replication (50% effective concentration [EC50] from 173 nM to 307 nM). Most importantly, Vebicorvir suppressed covalently closed circular DNA (cccDNA) formation in two de novo infection models with EC50s from 1.84 μM to 7.3 μM. Mechanism-of-action studies indicated that Vebicorvir is a direct-acting antiviral that targets HBV core protein, preventing HBV pregenomic RNA (pgRNA) encapsidation and subsequent DNA replication.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

DBT, CHB, antiviral, ABI-H 0731, ABI-H0731, ABI-H-0731, inhibit, Inhibitor, Hepatitis B virus, HBV DNA, HBV, Vebicorvir

Compound Identifiers

PubChem CID

139394142